# Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma

> **NCT01392209** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Brain Cancer
- MALIGNANT GLIOMA
- Glioblastoma
- Anaplastic Astrocytoma (AA)
- Anaplastic Oligodendroglioma (AO)
- Anaplastic Oligo-astrocytoma (AOA)
- Anaplastic Mixed Gliomas
- Malignant Glioma NOS

## Interventions

- **OTHER:** Bevacizumab & Stereotactic Radiotherapy

## Key facts

- **NCT ID:** NCT01392209
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-08
- **Primary completion:** 2019-11-15
- **Final completion:** 2019-11-15
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-11-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01392209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01392209, "Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01392209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*